companies

Swing Therapeutics Seed

Employees 10+
Primary contact

Links
https://swingtherapeutics.com/
🏦 Potential exit path: M&A
Founded in 2019, Swing Therapeutics is developing digital treatments in disease areas where patients are not well-served. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company's near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.
Employees 10+
Primary contact

Links
https://swingtherapeutics.com/

Funding 💰

Total $9M
Last round 🔗 August 11, 2021.
Select investors JAZZ Venture Partners

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Swing Therapeutics received FDA's Breakthrough Device Designation for its digital therapeutic for the management of fibromyalgia. 🔗
  • The company's experienced CEO has previously held senior positions at the genomic diagnostics company Veracyte. Before that, he worked at a VC firm and McKinsey.
  • The market for digital therapeutics is expected to reach $13.1 billion by 2026. 🔗
  • Swing Therapeutics could be an attractive acquisition target for a major pharmaceutical company looking to expand into digital therapeutics.
Last update: September 6, 2021